Open Access Repository

Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery

Graham, MM, Sessler, DI, Parlow, JL, Biccard, BM, Guyatt, G, Leslie, K, Chan, MTV, Meyhoff, CS, Xavier, D, Sigamani, A, Kumar, PA, Mrkobrada, M, Cook, DJ, Tandon, V, Alvarez-Garcia, J, Villar, JC, Painter, TW, Landoni, G, Fleischmann, E, Lamy, A, Whitlock, R, Le Manach, Y, Aphang-Lam, M, Cata, JP, Gao, P, Terblanche, NCS, Ramana, PV, Jamieson, KA, Bessissow, A, Mendoza, GR, Ramirez, S, Diemunsch, PA, Yusuf, S and Devereaux, PJ 2018 , 'Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery' , Annals of Internal Medicine, vol. 168, no. 4 , pp. 237-244 , doi: 10.7326/M17-2341.

Full text not available from this repository.

Abstract

Background: Uncertainty remains about the effects of aspirin in patients with prior percutaneous coronary intervention (PCI) having noncardiac surgery.Objective: To evaluate benefits and harms of perioperative aspirin in patients with prior PCI.Design: Nonprespecified subgroup analysis of a multicenter factorial trial. Computerized Internet randomization was done between 2010 and 2013. Patients, clinicians, data collectors, and outcome adjudicators were blinded to treatment assignment. (ClinicalTrials.gov: NCT01082874).Setting: 135 centers in 23 countries.Patients: Adults aged 45 years or older who had or were at risk for atherosclerotic disease and were having noncardiac surgery. Exclusions were placement of a bare-metal stent within 6 weeks, placement of a drug-eluting stent within 1 year, or receipt of nonstudy aspirin within 72 hours before surgery.Intervention: Aspirin therapy (overall trial, n = 4998; subgroup, n = 234) or placebo (overall trial, n = 5012; subgroup, n = 236) initiated within 4 hours before surgery and continued throughout the perioperative period. Of the 470 subgroup patients, 99.9% completed follow-up.Measurements: The 30-day primary outcome was death or nonfatal myocardial infarction; bleeding was a secondary outcome.Results: In patients with prior PCI, aspirin reduced the risk for the primary outcome (absolute risk reduction, 5.5% [95% CI, 0.4% to 10.5%]; hazard ratio [HR], 0.50 [CI, 0.26 to 0.95]; P for interaction = 0.036) and for myocardial infarction (absolute risk reduction, 5.9% [CI, 1.0% to 10.8%]; HR, 0.44 [CI, 0.22 to 0.87]; P for interaction = 0.021). The effect on the composite of major and life-threatening bleeding in patients with prior PCI was uncertain (absolute risk increase, 1.3% [CI, -2.6% to 5.2%]). In the overall population, aspirin increased the risk for major bleeding (absolute risk increase, 0.8% [CI, 0.1% to 1.6%]; HR, 1.22 [CI, 1.01 to 1.48]; P for interaction = 0.50).Limitation: Nonprespecified subgroup analysis with small sample.Conclusion: Perioperative aspirin may be more likely to benefit rather than harm patients with prior PCI.

Item Type: Article
Authors/Creators:Graham, MM and Sessler, DI and Parlow, JL and Biccard, BM and Guyatt, G and Leslie, K and Chan, MTV and Meyhoff, CS and Xavier, D and Sigamani, A and Kumar, PA and Mrkobrada, M and Cook, DJ and Tandon, V and Alvarez-Garcia, J and Villar, JC and Painter, TW and Landoni, G and Fleischmann, E and Lamy, A and Whitlock, R and Le Manach, Y and Aphang-Lam, M and Cata, JP and Gao, P and Terblanche, NCS and Ramana, PV and Jamieson, KA and Bessissow, A and Mendoza, GR and Ramirez, S and Diemunsch, PA and Yusuf, S and Devereaux, PJ
Keywords: percutaneous intervention, aspirin, myocardial infarct, non-cardiac surgery
Journal or Publication Title: Annals of Internal Medicine
Publisher: Amer Coll Physicians
ISSN: 0003-4819
DOI / ID Number: 10.7326/M17-2341
Copyright Information:

Copyright 2018 American College of Physicians

Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP